Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2010 08:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Acquires New Internet Domain Rights

PHILADELPHIA, Feb. 23, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc.(NYSE Amex:HEB) (the "Company"), announces that the Company has recently secured all material rights, primarily for future and...
February 11, 2010 16:31 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Award of 2009 Executive Bonuses

PHILADELPHIA, Feb. 11, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") announces that the Board of Directors of Hemispherx Biopharma, Inc. has approved the...
February 08, 2010 08:45 ET | Source: Hemispherx Biopharma, Inc.

New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen(R), an Experimental Therapeutic

PHILADELPHIA, Feb. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") reported a recent study, published in the December 20th issue of Virology (2009) by a...
February 04, 2010 08:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Appoints Two Senior Pharma Executives to Key Manufacturing Positions

PHILADELPHIA, Feb. 4, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") announced today the appointments of Dr. Christopher Cavalli and Mr. Robert Fidanza. Dr....
February 02, 2010 10:02 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response

PHILADELPHIA, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced that the Company, via its manufacturing subcontractor, received a...
January 28, 2010 13:36 ET | Source: Hemispherx Biopharma, Inc.

Stanford University Publishes New Data on Immuno-potential of Hemispherx's Ampligen(R)

PHILADELPHIA, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced the publication of a peer-reviewed article providing study data on...
January 14, 2010 12:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Provides Grant to IACFS to Assist in the Development of Chronic Fatigue Syndrome (CFS) Clinical Guidelines

PHILADELPHIA, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that it has provided an un-restricted grant to the International...
January 14, 2010 09:46 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Addresses Ampligen(R) CFS Preclinical Issues

PHILADELPHIA, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") stated that on January 14, 2010, the Company submitted reports of new preclinical data...
December 16, 2009 16:56 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Addresses Ampligen(R) Manufacturing Issues

PHILADELPHIA, Dec. 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), stated that on December 11, 2009, the Company, via its manufacturing subcontractor, in...
December 02, 2009 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Investor Conference Call

PHILADELPHIA, Dec. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announces an investor update by teleconference on Thursday, December 3, 2009 at 10:00am EST. The update will...